Pay in 4 interest-free payments of $6.60 Learn more
Ships within 48 hours · Estimated delivery Jul 31 - Aug 5
Phase 2 Trial Design Participants: 338 adults with obesity (BMI 30) or overweight with comorbidities (BMI 27), without diabetes Duration: 48 weeks Dosing groups: Placebo, 1mg, 4mg, 8mg, or 12mg weekly (with gradual dose escalation over 20-24 weeks) Primary endpoint: Percentage change in body weight from baseline Beyond Weight Loss: Metabolic Improvements Beyond weight loss, the 12mg dose also improved several cardiometabolic markers: Blood pressure: Systolic BP decreased by 7.4 mmHg (clinically significant reduction) Lipids: Triglycerides fell 30%, HDL cholesterol increased 8% Glucose control: HbA1c decreased 0.4% even in participants without diabetes Liver health: Markers of fatty liver disease (ALT, AST) improved significantly Inflammation: C-reactive protein (CRP) decreased, indicating reduced systemic inflammation What this means: Retatrutide appears to improve the metabolic dysfunction behind obesity-related diseases, not just the weight itself
It is very important to understand that steroid injections do not cure alopecia areata but they temporarily or permanently resolve a patch
& Gonzalez, A
Does this supplement improve skin and hair health
ACE inhibitors
Absorption of Radioactive Vitamin B12 after Total Gastrectomy
US$ 24.26
US$ 21.31
US$ 26.01
US$ 27.00
US$ 22.66
